Spatial Transcriptomics in Kidney Transplantation

Condition(s) studied

Investigational drug(s) / intervention(s)

Non interventional: Non interventional. Review of clinical, biopsy (histopathological and molecular) features associated with rejection and non-rejection pathology diagnosis

Study summary

The study is an investigator-led, prospective, longitudinal, observational cohort study.

The central hypothesis for this study is that spatial data will reveal new insights to immune cell function and local interactions within the kidney tissue to better predict important clinical outcomes. Investigators aspire to establish a prospective, longitudinal cohort to improve the diagnosis and management of kidney transplant rejection using precision pathology.

By utilising new spatial technologies, the investigators aim to:

* Derive a spatially resolved transcriptomic signature of kidney transplant rejection subtypes
* Derive accurate transcriptomic signatures aligned with key cell types within the transplant kidney
* Develop refinements to histological kidney rejection diagnostic and scoring classification
* Correlate of spatial and refined biopsy scoring features to clinically important outcomes

Eligibility

Primary outcome measure(s)

• Kidney biopsy features — At biopsy or during study follow up following biopsy during study (expected 12-months)
  Based on the pathology subtype at original diagnosis
• Kidney biopsy transcriptomic signature — At biopsy - based on collected tissue sample
  Based on bulk and/or spatial transcriptomic experiments
• Kidney cell type composition — At biopsy - based on collected tissue sample
  Cell type phenotyping of immune and kidney cell types

Trial sites (1)

More Western Sydney Local Health District trials in Australia